About Caped
Tianjin Caped Medical Equipment Co.,Ltd. is a biotechnology company specializing in the R&D, production, sales, and service of In Vitro Diagnostic (IVD) products,with 20 years of industry experience. We provide comprehensiverapid diagnosis managementsolutions, helping healthcare systems worldwide to improve their efficiency and patient care.
We specialize in the development of high-quality IVD products, including:
- Diagnostic Reagents(Test Strips/Test Kits for Human or Animal)
- Biological Raw Materials
- Diagnostic Equipment
CAPED dedicated to offering customers comprehensive and diversified IVD products and services. Customer needs guide our direction, and we are steadfast in keeping pace with the market, aspiring to become leaders in the field of In Vitro Diagnostic.
Product Series
Featured Products
Why Caped
Professional Manufacturers ，Sell Independently
Efficient Production &Timely Delivery
20 Years Accumulation, Industry Leadership
International Famous Brand Cooperation
Global Sales Network
Professional R&D Team, Customized Design
Latest News and Blog
5 Facts You Need to Know about Mycoplasma pneumoniae
In recent times, there has been a notable increase in cases of pediatric pneumonia linked to Mycoplasma pneumoniae (MP) in several countries, including China, Denmark, France, the Netherlands, and specific regions in the United States. This rise has raised concerns on a global scale. Although MP is known to cause occasional outbreaks, experts believe that the current increase may be more significant than usual, particularly in Europe and Asia, where reported cases have quadrupled compared to previous years. In order to understand what MP is all about, here are 5 facts listed below. 1. MP infections typically present with mild symptoms such as low-grade fever, dry cough, mild shortness of breath (especially during physical activity), and fatigue. The symptoms of Mycoplasma pneumonia (MP) differ from those caused by typical pneumonia bacteria like Streptococcus and Haemophilus. MP infections generally do not exhibit severe shortness of breath, high fever, or productive cough. Instead, patients commonly experience low-grade fever, dry cough, mild shortness of breath (especially during physical activity), and fatigue. MP can sometimes resemble an upper respiratory infection or common cold rather than a lower respiratory infection or pneumonia. The most prominent sign of infection is a dry cough. Other possible symptoms may
New RNA-Based Test Offers Hope in Global Tuberculosis Fight
Simpler, Faster Diagnostics Could Save Lives and Reduce Overtreatment 1.Tuberculosis: A Deadly but Treatable Disease In 2023, tuberculosis (TB) killed 1.25 million people worldwide. Despite being curable, TB remains the deadliest infectious disease. Powerful antibiotics can cure 88% of cases globally. However, 12% of patients see the disease return, often because doctors lack tools to confirm a full cure. 2.The Problem with Current TB Treatment “Right now, doctors use a one-size-fits-all approach,” said Dr. Kayvan Zainabadi, a microbiology expert at Weill Cornell Medicine. Patients take antibiotics for six months, even though 5-10% won’t be cured. Meanwhile, many recover faster but still finish unnecessary treatment. “We need a test to show who is cured and when,” he added. 3.RNA: A Game-Changer for TB Testing Dr. Zainabadi’s team is developing a test using 16S ribosomal RNA (rRNA) from TB bacteria. Unlike DNA, RNA breaks down quickly, reducing false positives. “DNA lingers long after cure, but RNA gives real-time clues,” he explained. This method could also detect TB in samples like saliva or urine, avoiding painful procedures for vulnerable groups like children. 4.Global Collaboration for Better Diagnostics The team partnered with clinics in Haiti, India, and Uganda to test their approach. For example,
Vaccine Breakthrough Offers Hope for Endangered California Condors
Bird Flu Vaccine Trial Shows Strong Immune Response, Averting a Conservation Crisis 1.A Race to Save North America’s Rarest Bird In 2023, a deadly strain of bird flu (HPAI) swept through California condor populations, killing 21 birds—nearly 18% of the northern Arizona and Utah flock. For a species already teetering on extinction due to lead poisoning, this outbreak was catastrophic. Today, fewer than 350 California condors exist worldwide. But a groundbreaking vaccine trial offers new hope. 2.Why Vaccines Matter for Wildlife Since 2020, the HPAI virus has caused a global outbreak in birds, spilling over into mammals. Wild birds like condors are especially vulnerable because they can carry the virus without showing symptoms. “When a species has only a few hundred left, every life counts,” researchers explain. Vaccines could prevent extinction by reducing deaths and slowing transmission. 3.From Lab to Field: Testing the Vaccine To ensure safety, scientists first tested a poultry flu vaccine on black vultures—a close relative of condors. “Vultures are easier to study, and their response helps us predict how condors might react,” the team noted. After promising results, they moved to condors. By October 2024, 207 condors had received at least one dose. 4.Key Findings: A
New Antibiotic Breakthrough Targets Drug-Resistant MRSA Infections
Lab-Developed Gel Could Revolutionize Treatment for Skin Superbugs 1.The Growing Threat of Antibiotic Resistance Superbugs are bacteria that resist common antibiotics. Every year, millions suffer from untreatable infections. MRSA, a deadly drug-resistant staph bacteria, is a major culprit. 2.A Promising Discovery: Epidermicin NI01 Scientists at the University of Plymouth have created epidermicin NI01—a new antibiotic. In lab tests, it fought MRSA as effectively as current drugs. Better yet, it caused fewer side effects. 3.How It Works The compound targets MRSA on the skin. Researchers tested it on wounds, including cuts and surgical sites. Results showed it could replace lengthy antibiotic courses. 4.From Lab to Clinic: The Path Forward Next, the team aims to turn the antibiotic into a gel. “Gels are easy to apply and reduce overuse of pills,” said Prof. Mathew Upton, lead researcher. Human trials could begin soon. 5.Why Current Treatments Are Failing Existing MRSA drugs often cause nausea, rashes, or organ damage. Worse, bacteria are evolving resistance. “Skin infections need safer, faster solutions,” Upton explained. 6.The Role of Innovation The project combines lab tests with AI-powered machine learning. This speeds up research and improves drug effectiveness. “AI helps us design better antibiotics,” the team noted. 7.Funding the
Qualification& Certification
Global Partners
